{"id":"insulin-sulfonylurea","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Gastrointestinal disturbances"}]},"_chembl":{"chemblId":"CHEMBL1201631","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin directly lowers blood glucose by promoting cellular uptake and utilization of glucose, while sulfonylureas bind to ATP-sensitive potassium channels on beta cells, triggering insulin release. Together, they address both insulin deficiency and insulin secretion capacity in type 2 diabetes management.","oneSentence":"This combination therapy uses insulin to provide exogenous glucose control while sulfonylureas stimulate endogenous insulin secretion from pancreatic beta cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:16:21.550Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05663515","phase":"","title":"A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-30","conditions":"Pancreatic Cancer","enrollment":24000},{"nctId":"NCT05042505","phase":"NA","title":"Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation","status":"COMPLETED","sponsor":"Medanta, The Medicity, India","startDate":"2022-01-01","conditions":"Diabetes Mellitus, Liver Transplant; Complications","enrollment":100},{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT02616666","phase":"PHASE4","title":"A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2016-08-25","conditions":"Type 2 Diabetes Mellitus","enrollment":632},{"nctId":"NCT01794143","phase":"PHASE3","title":"A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"GRADE Study Group","startDate":"2013-05","conditions":"Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications","enrollment":7850},{"nctId":"NCT00974090","phase":"PHASE3","title":"Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-09","conditions":"Type 2 Diabetes Mellitus","enrollment":194},{"nctId":"NCT07314684","phase":"PHASE4","title":"GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM","status":"RECRUITING","sponsor":"Federico II University","startDate":"2025-09-08","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":80},{"nctId":"NCT06528405","phase":"PHASE2","title":"The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-11-21","conditions":"Acute Kidney Injury","enrollment":264},{"nctId":"NCT04770532","phase":"PHASE3","title":"A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-03-05","conditions":"Diabetes Mellitus, Type 2","enrollment":526},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT00610038","phase":"PHASE2","title":"Efficacy and Safety Study of Sulfonylureas in Neonatal Diabetes Mellitus","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2006-07","conditions":"Diabetes Mellitus","enrollment":19},{"nctId":"NCT05687500","phase":"PHASE2","title":"Oral Glibenclamide in Preterm Infants With Hyperglycaemia (GALOP)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-05-20","conditions":"Transient; Hypoglycemia, Neonatal, Preterm, Glibenclamide Adverse Reaction","enrollment":35},{"nctId":"NCT05933174","phase":"NA","title":"Promoting Alternatives to Sulfonylureas to Improve Patient Safety in Type 2 Diabetes","status":"RECRUITING","sponsor":"Ian J. Neeland, MD","startDate":"2023-10-01","conditions":"Type2diabetes","enrollment":220},{"nctId":"NCT05214573","phase":"","title":"Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2021-12-01","conditions":"Type 2 Diabetes, Cardiac Disease","enrollment":386301},{"nctId":"NCT01731431","phase":"PHASE3","title":"Multicenter Randomized Trial of Non-inferiority Between Glyburide and Insulin for the Treatment of Gestational Diabetes","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-05-18","conditions":"Diabetes, Gestational","enrollment":914},{"nctId":"NCT07094529","phase":"NA","title":"Personalized Hypoglycemia Outpatient Treatment - a Feasibility Study","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2025-07-21","conditions":"Type 2 Diabetes (T2DM), Hypoglycemia (Diabetic)","enrollment":120},{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":"Diabetes Mellitus Type 2","enrollment":150},{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":714582},{"nctId":"NCT04294901","phase":"NA","title":"Engaging Patients to Promote Deprescribing","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2021-03-29","conditions":"Medical Overuse, Inappropriate Prescribing, Deprescriptions","enrollment":5946},{"nctId":"NCT02695121","phase":"","title":"Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-01-01","conditions":"Breast Cancer, Bladder Cancer","enrollment":2133575},{"nctId":"NCT03029702","phase":"PHASE4","title":"Metabolic Analysis for Treatment Choice in Gestational Diabetes Mellitus","status":"COMPLETED","sponsor":"Maisa N. Feghali, MD","startDate":"2018-02-28","conditions":"Gestational Diabetes, Diabetes, Gestational, Pregnancy in Diabetes","enrollment":54},{"nctId":"NCT04017221","phase":"","title":"Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-10-01","conditions":"Diabetes Mellitus, Type 2, Urosepsis, Diabetic Ketoacidosis","enrollment":1249636},{"nctId":"NCT01107717","phase":"PHASE4","title":"Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2009-01","conditions":"Diabetes","enrollment":318},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT05284344","phase":"","title":"The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Adelaide","startDate":"2021-01-24","conditions":"Type 2 Diabetes","enrollment":78},{"nctId":"NCT06203275","phase":"PHASE3","title":"The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"aya ramadan ashmawy sarhan","startDate":"2024-01","conditions":"Diabetes Mellitus, Type 2","enrollment":44},{"nctId":"NCT04572165","phase":"","title":"Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data","status":"UNKNOWN","sponsor":"Novo Nordisk A/S","startDate":"2021-01-26","conditions":"Diabetes Mellitus, Type 2","enrollment":600000},{"nctId":"NCT05360537","phase":"PHASE4","title":"Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2021-04-01","conditions":"Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT00267683","phase":"PHASE3","title":"Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2005-12","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":9},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":550000},{"nctId":"NCT03862963","phase":"NA","title":"Lifestyle Intervention to Treat Diabetes in the Marshall Islands","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2006-06-01","conditions":"Type 2 Diabetes Mellitus","enrollment":138},{"nctId":"NCT02029846","phase":"PHASE4","title":"Glycemia in Diabetic Elders Trial","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2013-04","conditions":"Type 2 Diabetes Mellitus","enrollment":2},{"nctId":"NCT03871621","phase":"PHASE4","title":"Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2019-04-01","conditions":"Type 2 Diabetes Mellitus","enrollment":76},{"nctId":"NCT04093752","phase":"PHASE3","title":"A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-12-09","conditions":"Type 2 Diabetes","enrollment":917},{"nctId":"NCT02921906","phase":"NA","title":"Effect of Food Composition on Postprandial Insulin Secretion in Neonatal Diabetes","status":"COMPLETED","sponsor":"Royal Devon and Exeter NHS Foundation Trust","startDate":"2016-06","conditions":"Neonatal Diabetes","enrollment":16},{"nctId":"NCT05565976","phase":"PHASE2, PHASE3","title":"Dapagliflozin Effect in Cognitive Impairment in Stroke Trial","status":"UNKNOWN","sponsor":"Jaime Daniel Mondragon","startDate":"2020-08-01","conditions":"Stroke, Ischemic, Mild Cognitive Impairment, Dementia, Vascular","enrollment":270},{"nctId":"NCT01986881","phase":"PHASE3","title":"Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-11-04","conditions":"Type 2 Diabetes Mellitus","enrollment":8246},{"nctId":"NCT02272556","phase":"NA","title":"Investigating the Role of the Polyol Pathway in the Central Nervous System","status":"COMPLETED","sponsor":"Yale University","startDate":"2015-02","conditions":"Hyperglycemia","enrollment":138},{"nctId":"NCT03486964","phase":"","title":"Use of Incretins in Diabetic Patients","status":"COMPLETED","sponsor":"University of Pavia","startDate":"2018-03-27","conditions":"Diabetes Mellitus, Type 2","enrollment":2234},{"nctId":"NCT05386186","phase":"PHASE4","title":"The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-01-01","conditions":"Diabetes Mellitus, Type 2, Severe Insulin Deficient Diabetes","enrollment":192},{"nctId":"NCT05360147","phase":"PHASE3","title":"Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Third Military Medical University","startDate":"2021-01-20","conditions":"Type 2 Diabetes Mellitus","enrollment":30},{"nctId":"NCT02836704","phase":"PHASE4","title":"Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-09-09","conditions":"Diabetes Mellitus, Type 2","enrollment":892},{"nctId":"NCT02941367","phase":"PHASE4","title":"Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-02-23","conditions":"Diabetes Mellitus, Type 2","enrollment":184},{"nctId":"NCT04283318","phase":"NA","title":"Prolonged Fasting on Glucose Metabolism and Hormonal Regulation in Healthy, Obese and Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2018-06-13","conditions":"Healthy, Obesity, Type 2 Diabetes Mellitus","enrollment":80},{"nctId":"NCT05041673","phase":"NA","title":"Anti-diabetic Drugs and Fatty Liver Management","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2021-02-23","conditions":"Fatty Liver, Nonalcoholic, Diabetes Mellitus, Type 2","enrollment":120},{"nctId":"NCT04272359","phase":"","title":"Substitution of Sulfonylureas With New Generation of Hypoglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"University of Milan","startDate":"2019-05-06","conditions":"T2DM (Type 2 Diabetes Mellitus), Diet, Healthy, Renal Function Disorder","enrollment":138},{"nctId":"NCT05055219","phase":"","title":"Conventional and Metabolomic Predictors of Prediabetes & Insulin Resistance","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2015-06","conditions":"PreDiabetes, Obesity, Childhood","enrollment":772},{"nctId":"NCT02922179","phase":"","title":"Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics","status":"COMPLETED","sponsor":"Biologics & Biosimilars Collective Intelligence Consortium","startDate":"2011-01-01","conditions":"Diabetes","enrollment":103951},{"nctId":"NCT03430284","phase":"PHASE4","title":"Multifactorial Intervention on Diabetes (MIDiab Study)","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2018-04-01","conditions":"Diabetes Mellitus, Type 2","enrollment":6300},{"nctId":"NCT04146155","phase":"PHASE4","title":"Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-01","conditions":"Type 2 Diabetes, Peripheral Vascular Disorder Due to Diabetes Mellitus","enrollment":200},{"nctId":"NCT03049228","phase":"","title":"In and ex Vivo Mitochondrial Function of the Heart","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2017-03-21","conditions":"Diabetes Mellitus, Type 2, Diabetic Cardiomyopathies","enrollment":38},{"nctId":"NCT02973477","phase":"PHASE4","title":"Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2017-01-12","conditions":"Type2 Diabetes, Cardiovascular Diseases","enrollment":45},{"nctId":"NCT01033773","phase":"NA","title":"Stop Emergency Room Visits for Hyperglycemia Project - District of Columbia (DC)","status":"COMPLETED","sponsor":"Medstar Health Research Institute","startDate":"2007-09","conditions":"Type 2 Diabetes Mellitus","enrollment":86},{"nctId":"NCT03705195","phase":"NA","title":"Study of Sulphonylurea Synergy With Incretins","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2018-08-03","conditions":"Type 2 Diabetes Mellitus","enrollment":20},{"nctId":"NCT02624830","phase":"PHASE4","title":"Long-Term Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR)","status":"UNKNOWN","sponsor":"Haukeland University Hospital","startDate":"2019-02-15","conditions":"Permanent Neonatal Diabetes Mellitus","enrollment":30},{"nctId":"NCT02043054","phase":"PHASE3","title":"Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Disease","enrollment":90},{"nctId":"NCT04239586","phase":"PHASE4","title":"Switching From Insulin to Sulfonylurea in Diabetes Associated With Variants in MODY Genes","status":"UNKNOWN","sponsor":"Haukeland University Hospital","startDate":"2017-04-18","conditions":"Maturity-Onset Diabetes of the Young, Type 3, Maturity Onset Diabetes of the Young, Type 1, Childhood Diabetes Mellitus","enrollment":30},{"nctId":"NCT01648582","phase":"PHASE3","title":"A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07","conditions":"Type 2 Diabetes Mellitus","enrollment":774},{"nctId":"NCT02686476","phase":"NA","title":"Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Medanta, The Medicity, India","startDate":"2016-03","conditions":"Non Alcoholic Fatty Liver Disease","enrollment":100},{"nctId":"NCT03081676","phase":"NA","title":"The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2017-03-08","conditions":"Maturity-Onset Diabetes of the Young, Type 3","enrollment":20},{"nctId":"NCT02128932","phase":"PHASE3","title":"Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-08-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1089},{"nctId":"NCT02188186","phase":"PHASE4","title":"Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-07","conditions":"Type 2 Diabetes","enrollment":200},{"nctId":"NCT01894568","phase":"PHASE3","title":"A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-07","conditions":"Type 2 Diabetes Mellitus","enrollment":388},{"nctId":"NCT03507829","phase":"PHASE3","title":"Insulin Therapy for the Prevention of New Onset Diabetes After Transplantation Prospective Study in Non-Diabetic De Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2012-11-21","conditions":"Hyperglycemia","enrollment":263},{"nctId":"NCT02453685","phase":"PHASE4","title":"A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-08-31","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":335},{"nctId":"NCT03421119","phase":"PHASE3","title":"Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes","status":"UNKNOWN","sponsor":"Cinnagen","startDate":"2019-06-20","conditions":"Diabetes Mellitus, Type 2","enrollment":300},{"nctId":"NCT03050619","phase":"","title":"Characteristics of Empagliflozin Initiators","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-09-10","conditions":"Type 2 Diabetes","enrollment":31908},{"nctId":"NCT02954692","phase":"PHASE4","title":"A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-11-30","conditions":"Type 2 Diabetes Mellitus","enrollment":112},{"nctId":"NCT02551874","phase":"PHASE3","title":"A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-10-20","conditions":"Type 2 Diabetes Mellitus","enrollment":650},{"nctId":"NCT02219750","phase":"PHASE4","title":"Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2013-08","conditions":"Diabetes","enrollment":181},{"nctId":"NCT01698775","phase":"PHASE3","title":"A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-02","conditions":"Type 2 Diabetes Mellitus","enrollment":213},{"nctId":"NCT02109978","phase":"","title":"RetroMASTER - Retrospective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes","status":"COMPLETED","sponsor":"Royal Devon and Exeter NHS Foundation Trust","startDate":"2013-04","conditions":"Diabetes","enrollment":562},{"nctId":"NCT02105792","phase":"","title":"PROMASTER - PROspective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes","status":"COMPLETED","sponsor":"Royal Devon and Exeter NHS Foundation Trust","startDate":"2013-03","conditions":"Diabetes","enrollment":820},{"nctId":"NCT01680185","phase":"PHASE3","title":"Sensor-Augmented Insulin-Pump Therapy in New-onset Diabetes After Transplantation","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2012-08","conditions":"Hyperglycemia","enrollment":85},{"nctId":"NCT01215331","phase":"PHASE3","title":"Gestational Diabetes: Insulin or Oral Hypoglycemic Agents?","status":"COMPLETED","sponsor":"Université de Sherbrooke","startDate":"2010-08","conditions":"Gestational Diabetes Mellitus","enrollment":73},{"nctId":"NCT00194896","phase":"NA","title":"Preferred Treatment of Type 1.5 Diabetes","status":"COMPLETED","sponsor":"University of Washington","startDate":"2000-02","conditions":"Type 2 Diabetes Mellitus","enrollment":64},{"nctId":"NCT00451620","phase":"PHASE2","title":"Effect of GlucoNorm vs Glyburide on Post-Prandial Hyperglycemia in Elderly Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2003-11","conditions":"Type 2 Diabetes","enrollment":30},{"nctId":"NCT00232583","phase":"NA","title":"Preservation of Beta-cell Function in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2003-11","conditions":"Type 2 Diabetes Mellitus","enrollment":58},{"nctId":"NCT03249506","phase":"","title":"Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-05-12","conditions":"Diabetes Mellitus, Type 2","enrollment":25358},{"nctId":"NCT01618162","phase":"PHASE3","title":"The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-08-29","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":435},{"nctId":"NCT02624817","phase":"PHASE4","title":"Long-Term Sulfonylurea Response in KCNJ11 Neonatal Diabetes","status":"COMPLETED","sponsor":"Haukeland University Hospital","startDate":"2015-12","conditions":"Permanent Neonatal Diabetes Mellitus","enrollment":90},{"nctId":"NCT02857764","phase":"","title":"Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-02-15","conditions":"Diabetes Mellitus, Type 2","enrollment":127690},{"nctId":"NCT01357135","phase":"","title":"An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-07-15","conditions":"Type 2 Diabetes Mellitus","enrollment":3453},{"nctId":"NCT01798706","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Type 2 Diabetes","enrollment":350},{"nctId":"NCT00789191","phase":"PHASE3","title":"Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":222},{"nctId":"NCT01720303","phase":"PHASE4","title":"Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-09-19","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":159},{"nctId":"NCT02140645","phase":"","title":"Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-05","conditions":"Diabetes Mellitus, Type 2","enrollment":166613},{"nctId":"NCT02269098","phase":"NA","title":"The Synergy to Control Emergency Department Hyperglycemia Program for Type 2 Diabetes","status":"COMPLETED","sponsor":"Medstar Health Research Institute","startDate":"2012-02","conditions":"Diabetes Mellitus, Type 2, Medication Adherence, HYPERGLYCEMIA","enrollment":101},{"nctId":"NCT00313001","phase":"PHASE3","title":"Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":373},{"nctId":"NCT02080377","phase":"PHASE3","title":"A Feasibility Study Looking at the Use of Glibenclamide and metfoRmin Versus stAndard Care in gEstational diabeteS","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2014-07","conditions":"Pregnancy, Gestational Diabetes","enrollment":23},{"nctId":"NCT01649466","phase":"PHASE4","title":"Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-08","conditions":"Type 2 Diabetes Mellitus","enrollment":162},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":1417914},{"nctId":"NCT01051011","phase":"PHASE3","title":"A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2010-01","conditions":"Diabetes Mellitus Type 2","enrollment":370},{"nctId":"NCT00866658","phase":"PHASE3","title":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-03","conditions":"Diabetes Mellitus, Type 2","enrollment":311},{"nctId":"NCT01944618","phase":"","title":"forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2013-10","conditions":"Type 2 Diabetes","enrollment":5000},{"nctId":"NCT02887625","phase":"NA","title":"Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM","status":"UNKNOWN","sponsor":"Dr. Muhammad Abdulghani","startDate":"2015-02","conditions":"Type 2 Diabetes","enrollment":410},{"nctId":"NCT00755287","phase":"PHASE3","title":"A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-11","conditions":"Diabetes Mellitus Type 2","enrollment":1072},{"nctId":"NCT02282423","phase":"NA","title":"PGC-1 & Muscle Mitochondrial Dysfunction in Diabetes","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2014-05","conditions":"Diabetes, Obesity","enrollment":26},{"nctId":"NCT01947699","phase":"PHASE4","title":"Glycemic Profile in Women With Gestational Diabetes Treated With Glyburide","status":"WITHDRAWN","sponsor":"University of Pittsburgh","startDate":"2013-09","conditions":"Gestational Diabetes","enrollment":""},{"nctId":"NCT01871558","phase":"PHASE3","title":"Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-06","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":75,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Insulin, sulfonylurea","genericName":"Insulin, sulfonylurea","companyName":"University of Pittsburgh","companyId":"university-of-pittsburgh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy uses insulin to provide exogenous glucose control while sulfonylureas stimulate endogenous insulin secretion from pancreatic beta cells. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}